Cutler Group’s Lipocine LPCN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-765
| Closed | -$2K | – | 4019 |
|
|
2023
Q3 | $2K | Hold |
765
| – | – | ﹤0.01% | 3287 |
|
|
2023
Q2 | $3K | Hold |
765
| – | – | ﹤0.01% | 2868 |
|
|
2023
Q1 | $4K | Hold |
765
| – | – | ﹤0.01% | 2839 |
|
|
2022
Q4 | $5K | Hold |
765
| – | – | ﹤0.01% | 3187 |
|
|
2022
Q3 | $5K | Hold |
765
| – | – | ﹤0.01% | 3670 |
|
|
2022
Q2 | $10K | Sell |
765
-53
| -6% | -$826 | ﹤0.01% | 3203 |
|
|
2022
Q1 | $19K | Buy |
818
+53
| +7% | +$1.11K | ﹤0.01% | 3103 |
|
|
2021
Q4 | $12K | Hold |
765
| – | – | ﹤0.01% | 3547 |
|
|
2021
Q3 | $14K | Hold |
765
| – | – | ﹤0.01% | 3657 |
|
|
2021
Q2 | $18K | Hold |
765
| – | – | ﹤0.01% | 3395 |
|
|
2021
Q1 | $19K | Hold |
765
| – | – | ﹤0.01% | 3261 |
|
|
2020
Q4 | $17K | Hold |
765
| – | – | ﹤0.01% | 2797 |
|
|
2020
Q3 | $18K | Hold |
765
| – | – | ﹤0.01% | 2522 |
|
|
2020
Q2 | $16K | Hold |
765
| – | – | ﹤0.01% | 2545 |
|
|
2020
Q1 | $6K | Hold |
765
| – | – | ﹤0.01% | 2999 |
|
|
2019
Q4 | $5K | Hold |
765
| – | – | ﹤0.01% | 3054 |
|
|
2019
Q3 | $36K | Hold |
765
| – | – | ﹤0.01% | 1772 |
|
|
2019
Q2 | $25K | Hold |
765
| – | – | ﹤0.01% | 2030 |
|
|
2019
Q1 | $30K | Hold |
765
| – | – | ﹤0.01% | 1777 |
|
|
2018
Q4 | $16K | Hold |
765
| – | – | ﹤0.01% | 2259 |
|
|
2018
Q3 | $17K | Hold |
765
| – | – | ﹤0.01% | 2346 |
|
|
2018
Q2 | $16K | Sell |
765
-34
| -4% | -$810 | ﹤0.01% | 2343 |
|
|
2018
Q1 | $20K | Buy |
799
+299
| +60% | +$8.32K | ﹤0.01% | 2295 |
|
|
2017
Q4 | $29K | Sell |
500
-65
| -12% | -$4.04K | ﹤0.01% | 2262 |
|
|
2017
Q3 | $38K | Sell |
565
-104
| -16% | -$7.52K | ﹤0.01% | 2499 |
|
|
2017
Q2 | $45K | Sell |
669
-408
| -38% | -$26.6K | ﹤0.01% | 2593 |
|
|
2017
Q1 | $71K | Buy |
1,077
+253
| +31% | +$16.4K | ﹤0.01% | 2056 |
|
|
2016
Q4 | $51K | Buy |
824
+18
| +2% | +$1.14K | ﹤0.01% | 2522 |
|
|
2016
Q3 | $61K | Sell |
806
-312
| -28% | -$19.3K | ﹤0.01% | 2256 |
|
|
2016
Q2 | $57K | Buy |
1,118
+58
| +5% | +$8.98K | ﹤0.01% | 2223 |
|
|
2016
Q1 | $182K | Buy |
1,060
+931
| +722% | +$159K | 0.01% | 1077 |
|
|
2015
Q4 | $28K | Buy |
+129
| New | +$27.1K | ﹤0.01% | 3056 |
|
Other funds holding LPCN
WE
TRCT
Cutler Group's LPCN Position: Q4 2023 in Review
Cutler Group sold out of Lipocine (LPCN) in Q4 2023, closing a stake of 765 shares — an estimated $2K sold.
Cutler Group first reported a position in LPCN in Q4 2015 and held it in 32 quarters. The position peaked at $182K in Q1 2016. 19 funds tracked by Wall St. Rank hold LPCN as of Q4 2023.
- Cutler Group reported no remaining Lipocine position as of Q4 2023 after selling out during the quarter.
- Cutler Group sold 765 Lipocine shares in Q4 2023, an estimated $2K.
- Cutler Group first reported a position in Lipocine in Q4 2015 and held it in 32 quarters.
- Cutler Group's Lipocine position peaked at $182K in Q1 2016.
- 19 funds tracked by Wall St. Rank held Lipocine as of Q4 2023.
Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.